Target
TMPRSS2-ERG
6 abstracts
Abstract
Genomic alterations and self-reported Agent Orange exposure in United States veterans with metastatic prostate cancer.Org: David Geffen School of Medicine at University of California Los Angeles (UCLA), Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Veterans Affairs Greater Los Angeles Healthcare System, VA National Oncology Program and Durham VA Medical Center, University of Pennsylvania,
Abstract
Characterizing the molecular landscape of early onset and average onset prostate cancer.Org: University of Miami Miller School of Medicine, Miami, FL, Caris Life Sciences, Irving, TX, Huntsman Cancer Institute at the University of Utah, Huntsman Cancer Institute (NCI-CCC), University of California San Diego,
Abstract
Clinical factors associated with successful liquid tumor biopsy in men with prostate cancer.Org: Department of Veterans Affairs James Hailey Hospital, University of California Los Angeles, US Department of Veterans Affairs, University of Washington and Fred Hutchinson Cancer Research Centre, University of Washington Medical Center,
Abstract
Effect of SNPs in TMPRSS2 to severe COVID-19 in patients with prostate cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Molecular Immunology Unit, Department of Experimental Oncology, Programma Prostata,
Abstract
The impact of COVID-19 on mortality, length of stay, and cost of care among patients with gastrointestinal malignancies: A propensity score-matched analysis.Org: CHRISTUS Ochsner St. Patrick Hospital, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Keck Sch of Medicine, Univ of Southern California/Children's Oncology Group, Arcadia, CA, Washington University School of Medicine in St. Louis,
Abstract
Real-world genetic testing patterns in metastatic prostate cancer in Latin American (LATAM) population.Org: Instituto Alexander Fleming, Fundación Cancer - Fuca, Hospital Italiano de Buenos Aires, Sociedad de Oncología y Hematología del Cesar SOHEC, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru,